Acadia Pharmaceuticals Inc (ACAD) — 8-K Filings

8-K Filings (19)

• 8-K Filing — Nov 5, 2025
• Acadia Pharma Elects New Directors, Adjusts CMO Compensation — Nov 3, 2025 Risk: low
  Acadia Pharmaceuticals Inc. announced on October 28, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two n
• Acadia Pharmaceuticals Files 8-K on Financials — Aug 6, 2025 Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, and including financial statements a
• ACADIA Pharmaceuticals Files 8-K Report — Jun 10, 2025 Risk: low
  On June 9, 2025, ACADIA Pharmaceuticals Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding material event
• Acadia Pharmaceuticals Files 8-K on Shareholder Votes — May 29, 2025 Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on May 29, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific
• Acadia Pharmaceuticals Inc. Files 8-K — May 20, 2025 Risk: low
  On May 15, 2025, Acadia Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported on other events on this date. The filing wa
• Acadia Pharmaceuticals Files 8-K on Financials — May 7, 2025 Risk: low
  On May 7, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Acadia Pharmaceuticals Files 8-K Report — Apr 16, 2025 Risk: low
  On April 15, 2025, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and the
• Acadia Pharmaceuticals Files 8-K on Financials — Feb 26, 2025 Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on February 26, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Acadia Pharmaceuticals Completes Cerimon Therapeutics Acquisition — Dec 11, 2024 Risk: medium
  On December 11, 2024, ACADIA Pharmaceuticals Inc. reported the completion of its acquisition of all outstanding shares of Cerimon Therapeutics GmbH. The transac
• Acadia Pharma Names New Directors, Updates Exec Pay — Nov 20, 2024 Risk: low
  Acadia Pharmaceuticals Inc. announced on November 18, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two
• ACADIA Pharmaceuticals Files 8-K on Financials — Nov 6, 2024 Risk: low
  On November 6, 2024, ACADIA Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations,
• Acadia Pharmaceuticals Appoints New Directors, Updates Executive Contracts — Sep 23, 2024 Risk: low
  Acadia Pharmaceuticals Inc. announced on September 17, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two
• ACADIA Pharmaceuticals Files 8-K on Financials — Aug 6, 2024 Risk: low
  On August 6, 2024, ACADIA Pharmaceuticals Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Acadia Pharma Appoints New CMO, Elects Director — May 29, 2024 Risk: low
  Acadia Pharmaceuticals Inc. announced on May 29, 2024, the appointment of Dr. Anya Schiess as Chief Medical Officer and the election of Dr. David E. Michelson t
• Acadia Pharmaceuticals Files 8-K on Financials — May 8, 2024 Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on May 08, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Acadia Pharmaceuticals Files 8-K Report — Mar 11, 2024 Risk: low
  On March 11, 2024, Acadia Pharmaceuticals Inc. filed an 8-K report. The filing primarily serves as a notification of other events, with no specific material eve
• Acadia Pharma Files 8-K on Financial Results and Exhibits — Feb 27, 2024 Risk: low
  Acadia Pharmaceuticals Inc. filed an 8-K on February 27, 2024, to report on its "Results of Operations and Financial Condition" and "Financial Statements and Ex
• Acadia Pharma Reports Executive Compensation Changes — Jan 31, 2024
  Acadia Pharmaceuticals Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 30, 2024, related to changes in its executive compensa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX